NCT04776590View on ClinicalTrials.gov

Chemoradiotherapy Plus Immunotherapy Followed by Surgery for Esophageal Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 28, 2021

Primary Completion Date

March 11, 2023

Study Completion Date

December 15, 2024

Conditions
Esophagus CancerNeoadjuvant Therapy
Interventions
DRUG

Tislelizumab

neoadjuvant immunotherapy

Trial Locations (1)

430022

Union Hospital, Wuhan

Sponsors

Collaborators (1)

BeiGene
All Listed Sponsors
collaborator

BeiGene

INDUSTRY

lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

NCT04776590 - Chemoradiotherapy Plus Immunotherapy Followed by Surgery for Esophageal Cancer | Biotech Hunter | Biotech Hunter